BioCentury
ARTICLE | Clinical News

Coherus' CHS-131 meets Phase IIb MS endpoint

June 29, 2016 1:43 AM UTC

Coherus BioSciences Inc. (NASDAQ:CHRS) said a 3 mg dose of CHS-131 met the primary endpoint of a Phase IIb study to treat relapsing-remitting multiple sclerosis (RRMS). The dose, which was the higher of two in the trial, significantly reduced the cumulative number of total contrast-enhancing (CE) lesions from baseline to week 24 vs. placebo (p=0.01).

Coherus said the 3 mg dose reduced lesions by 46.3%. On a conference call Tuesday, CMO Barbara Finck said a 1 mg dose missed the endpoint. The study enrolled 227 treatment-naive patients. ...